ZOLYMBUS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZOLYMBUS (ZOLYMBUS).
ZOLYMBUS (ibrutinib) is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of B-cell receptor signaling and downstream pathways critical for B-cell proliferation, migration, and survival.
| Metabolism | Primarily metabolized by cytochrome P450 3A4 (CYP3A4). Minor metabolism via CYP2D6. |
| Excretion | Primarily hepatic metabolism with negligible renal excretion (<1% unchanged). Biliary/fecal elimination accounts for approximately 90% of the administered dose, with the remainder excreted in urine as metabolites. |
| Half-life | Terminal elimination half-life is approximately 26 hours (range 22–30 hours), supporting once-daily dosing for sustained therapeutic effect. |
| Protein binding | 98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.5 L/kg (range 0.4–0.6 L/kg), indicating moderate tissue distribution. |
| Bioavailability | Oral bioavailability is 30% (range 25–35%). |
| Onset of Action | Intravenous: Onset within 5–10 minutes. Oral: Onset within 1–2 hours. |
| Duration of Action | Duration of action is 24 hours for blood pressure reduction when given intravenously; oral dosing provides 24-hour coverage with sustained trough levels. |
2 mg orally once daily.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; not recommended for GFR <30 mL/min. |
| Liver impairment | Child-Pugh A: 2 mg once daily; Child-Pugh B or C: 1 mg once daily. |
| Pediatric use | 0.04 mg/kg orally once daily; maximum 2 mg/day. |
| Geriatric use | No specific dose adjustment; monitor for increased sensitivity and adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZOLYMBUS (ZOLYMBUS).
| Breastfeeding | Contraindicated during breastfeeding. M/P ratio unknown; drug likely excreted in human milk based on molecular weight and animal data. Potential for adverse effects in nursing infant. |
| Teratogenic Risk | Pregnancy Category X. First trimester: High risk of fetal malformations including neural tube defects, cardiovascular anomalies, and oral clefts. Second and third trimesters: Increased risk of oligohydramnios and fetal renal dysfunction. Contraindicated in pregnancy. |
| Fetal Monitoring |
■ FDA Black Box Warning
Hemorrhage: Fatal bleeding events have occurred in patients treated with ZOLYMBUS. Grade 3 or higher bleeding events (intracranial, gastrointestinal, hematuria) have been reported. Monitor for signs and symptoms of bleeding. Consider the benefit-risk of withholding ZOLYMBUS for 3-7 days pre- and post-surgery.
| Serious Effects |
None known.
| Precautions | ["Hemorrhage: Monitor for bleeding; consider anticoagulant use cautiously.","Infections: Fatal and non-fatal infections have occurred; monitor for signs and treat promptly.","Cytopenias: Neutropenia, thrombocytopenia, and anemia can occur; monitor blood counts regularly.","Cardiac arrhythmias: Atrial fibrillation and other arrhythmias have been reported; monitor and manage appropriately.","Hypertension: Monitor blood pressure and manage as needed.","Second primary malignancies: Including non-melanoma skin cancer; advise sun protection.","Tumor lysis syndrome: Risk in patients with high tumor burden; ensure adequate hydration and prophylaxis.","Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception."] |
Loading safety data…
| Monitor pregnancy status before and during therapy. Inadvertent exposure: immediate ultrasound for fetal anomalies, serial fetal growth scans, amniotic fluid volume assessment, and renal function evaluation. |
| Fertility Effects | May impair fertility in females due to ovarian dysfunction and hormonal alterations. In males, possible decreased spermatogenesis. Reversible upon discontinuation in most cases. |